InMode Prepares for Q4 2024 Financial Results Conference Call
InMode Anticipates Strong Fourth Quarter Revenue
InMode Ltd. (NASDAQ: INMD), a trailblazer in innovative medical technologies, is gearing up to announce its financial performance for the fourth quarter and the entire year of 2024. The company expects to publish its results before the opening of the Nasdaq market on February 6, 2025.
Details of the Upcoming Conference Call
The management team, including Chief Executive Officer Moshe Mizrahy, Chief Financial Officer Yair Malca, and Chief Technology Officer Dr. Michael Kreindel, will present their insights during the call scheduled for 8:30 a.m. Eastern Standard Time. This will be an excellent opportunity for investors and stakeholders to get a closer look at the company’s performance amid current market challenges.
Expected Revenue Highlights
According to preliminary figures, InMode is forecasting fourth-quarter revenue between $97.0 million and $97.5 million. For the entire year of 2024, anticipated revenue is projected to be between $394.0 million and $394.5 million.
Financial Projections for 2025
InMode also shares optimistic projections for 2025, estimating revenue could fall between $395 million and $405 million. These estimations reflect the company’s resilience in navigating challenges and positioning itself for growth.
How to Join the Conference Call
Participants are encouraged to pre-register for the conference call through the company’s designated link. This will grant them a unique dial-in code for seamless entry on the day of the event. For those unable to pre-register, alternative dial-in numbers will be available.
Replay Information
The company will provide a replay of the call for those unable to attend live. The playback will be accessible shortly after the call ends and will remain available for a full 90 days on InMode’s website.
About InMode Ltd.
InMode is recognized for its pioneering work in the field of medical technology, focusing on the development of solutions that leverage radiofrequency technology. The company's extensive product line supports a variety of procedures across different medical spheres, including plastic surgery, dermatology, gynecology, and more. With an ongoing commitment to innovation, InMode aims to enhance surgical practices and patient outcomes.
Frequently Asked Questions
What is the date of InMode's financial results announcement?
InMode's financial results will be announced on February 6, 2025.
Who are the key speakers during the conference call?
The conference call will feature CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel.
How can investors access the conference call?
Investors can pre-register online to receive a unique dial-in number or use a telephone number listed on the company’s announcement.
What financial outcomes is InMode expecting for Q4 2024?
The expected revenue for Q4 2024 ranges from $97.0 million to $97.5 million.
Where can I find more information about InMode's products?
More information about InMode and its medical technologies can be found on their official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.